bioAffinity Technologies, Inc. (BIAF)

bioAffinity Technologies' stock (BIAF) has experienced significant volatility over the past six months. While the stock saw a decline of 79.38% between April 11, 2025, and April 10, 2026, and a 79.51% decrease over the past year, there have been notable positive movements more recently. In the past month, the price increased by 193.81%, and over the last six months, it has risen by 17.13%. A surge occurred in March 2026 following the announcement of record 2025 sales for CyPath® Lung and a forecast of over 100% unit sales growth for 2026. Earnings reports have also impacted the stock, with dips after Q3 and Q2 earnings but a significant rise following a recent earnings release.

Based on historical data, bioAffinity Technologies, Inc. (BIAF) exhibits some demand seasonality for its products and services. March has historically been the strongest month, while September tends to be the weakest month. The company has an average annual return of -38.17% with a monthly win rate of 31.3%. The seasonal pattern for BIAF has a consistency score of 72.5, which is considered "Very Good."

bioAffinity Technologies, Inc. (BIAF) is a development-stage biotechnology company focused on non-invasive, early-stage cancer diagnosis and targeted cancer treatment. Its primary product, CyPath® Lung, is a non-invasive diagnostic test for early-stage lung cancer, utilizing flow cytometry and machine learning to analyze sputum samples. The company is also developing its platform for other lung diseases like asthma and COPD and operates through Diagnostic Research and Development, and Laboratory Services segments.

bioAffinity Technologies, Inc. is headquartered in San Antonio, Texas, with research and development facilities in the United States. The company is focused on expanding its U.S. market presence and exploring international licensing and distribution agreements. CyPath® Lung has seen increased adoption by physicians, including expansion into Veterans Administration (VA) medical centers and additional geographic markets within the U.S.

bioAffinity Technologies has actively worked to build its brand reputation through scientific engagement and highlighting the clinical value of CyPath® Lung. The company participates in scientific and medical forums, presenting data on CyPath® Lung. Positive events affecting its reputation include accelerating growth in CyPath® Lung test volume and revenues, driven by increased clinical adoption and outreach efforts. The company also highlights its expanding global patent estate.

The ownership structure of bioAffinity Technologies, Inc. (BIAF) stock includes public companies, retail, individual, and institutional investors. Public companies and individual investors hold approximately 99.55% of the company's stock, while institutional investors own about 0.45%. Major institutional owners include Geode Capital Management, Llc, Northern Trust Corp, Citadel Advisors Llc, and Morgan Stanley. STEVEN GIRGENTI is noted as owning the most shares among individual investors.